KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Taxes (2016 - 2025)

Historic Current Taxes for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to -$1.1 billion.

  • Astrazeneca's Current Taxes fell 55301.2% to -$1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 billion, marking a year-over-year decrease of 55301.2%. This contributed to the annual value of -$1.1 billion for FY2025, which is 55301.2% down from last year.
  • Astrazeneca's Current Taxes amounted to -$1.1 billion in Q4 2025, which was down 55301.2% from -$1.3 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Current Taxes ranged from a high of $1.6 billion in Q4 2023 and a low of -$1.7 billion during Q1 2025
  • Over the past 5 years, Astrazeneca's median Current Taxes value was -$800.5 million (recorded in 2022), while the average stood at -$533.4 million.
  • Its Current Taxes has fluctuated over the past 5 years, first surged by 25468.63% in 2021, then plummeted by 55301.2% in 2025.
  • Over the past 5 years, Astrazeneca's Current Taxes (Quarter) stood at $916.0 million in 2021, then fell by 2.18% to $896.0 million in 2022, then soared by 76.79% to $1.6 billion in 2023, then crashed by 110.48% to -$166.0 million in 2024, then crashed by 553.01% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q4 2025, -$1.3 billion for Q3 2025, and -$1.2 billion during Q2 2025.